Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLCγ1.

Meyer RD, Husain D, Rahimi N.

Oncogene. 2011 May 12;30(19):2198-206. doi: 10.1038/onc.2010.597. Epub 2011 Jan 17.

2.

Role of c-Cbl-dependent regulation of phospholipase Cgamma1 activation in experimental choroidal neovascularization.

Husain D, Meyer RD, Mehta M, Pfeifer WM, Chou E, Navruzbekov G, Ahmed E, Rahimi N.

Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6803-9. doi: 10.1167/iovs.10-5255. Epub 2010 Jun 30.

3.

A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis.

Singh AJ, Meyer RD, Navruzbekov G, Shelke R, Duan L, Band H, Leeman SE, Rahimi N.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5413-8. Epub 2007 Mar 19.

4.

A role for protein ubiquitination in VEGFR-2 signalling and angiogenesis.

Rahimi N.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1189-92. doi: 10.1042/BST0371189.

PMID:
19909244
5.

IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis.

Meyer RD, Sacks DB, Rahimi N.

PLoS One. 2008;3(12):e3848. doi: 10.1371/journal.pone.0003848. Epub 2008 Dec 3.

6.

Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells.

Meyer RD, Latz C, Rahimi N.

J Biol Chem. 2003 May 2;278(18):16347-55. Epub 2003 Feb 21. Erratum in: J Biol Chem. 2005 Jul 8;280(27):25948.

7.

Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGF-induced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1- and protein kinase A-dependent pathways.

Xiong Y, Huo Y, Chen C, Zeng H, Lu X, Wei C, Ruan C, Zhang X, Hu Z, Shibuya M, Luo J.

J Biol Chem. 2009 Aug 28;284(35):23217-24. doi: 10.1074/jbc.M109.019679. Epub 2009 Jul 1.

8.
9.

Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells.

Tahir SA, Park S, Thompson TC.

Cancer Biol Ther. 2009 Dec;8(23):2286-96. Epub 2009 Dec 19.

10.

Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation.

Reddi AL, Ying G, Duan L, Chen G, Dimri M, Douillard P, Druker BJ, Naramura M, Band V, Band H.

J Biol Chem. 2007 Oct 5;282(40):29336-47. Epub 2007 Jul 9.

11.

Essential role of calcium in vascular endothelial growth factor A-induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole.

Faehling M, Kroll J, Föhr KJ, Fellbrich G, Mayr U, Trischler G, Waltenberger J.

FASEB J. 2002 Nov;16(13):1805-7. Epub 2002 Sep 19.

PMID:
12354692
12.
13.
14.

CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.

Chung TW, Kim SJ, Choi HJ, Kwak CH, Song KH, Suh SJ, Kim KJ, Ha KT, Park YG, Chang YC, Chang HW, Lee YC, Kim CH.

J Mol Med (Berl). 2013 Feb;91(2):271-82. doi: 10.1007/s00109-012-0952-6. Epub 2012 Aug 31.

PMID:
22935775
15.

A dynamic constitutive and inducible binding of c-Cbl by PLCgamma1 SH3 and SH2 domains (negatively) regulates antigen receptor-induced PLCgamma1 activation in lymphocytes.

Rellahan BL, Graham LJ, Tysgankov AY, DeBell KE, Veri MC, Noviello C, Bonvini E.

Exp Cell Res. 2003 Sep 10;289(1):184-94.

PMID:
12941616
16.

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.

Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.

17.
18.

Cbl-b is a negative regulator of inflammatory cytokines produced by IgE-activated mast cells.

Gustin SE, Thien CB, Langdon WY.

J Immunol. 2006 Nov 1;177(9):5980-9.

19.

The c-Cbl ubiquitin ligase regulates nuclear β-catenin and angiogenesis by its tyrosine phosphorylation mediated through the Wnt signaling pathway.

Shivanna S, Harrold I, Shashar M, Meyer R, Kiang C, Francis J, Zhao Q, Feng H, Edelman ER, Rahimi N, Chitalia VC.

J Biol Chem. 2015 May 15;290(20):12537-46. doi: 10.1074/jbc.M114.616623. Epub 2015 Mar 17.

20.

sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways.

Kim BR, Seo SH, Park MS, Lee SH, Kwon Y, Rho SB.

Oncotarget. 2015 Oct 13;6(31):31830-43. doi: 10.18632/oncotarget.5570.

Supplemental Content

Support Center